Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.
| Original language | English (US) |
|---|---|
| Pages | 32-35 |
| Number of pages | 4 |
| Volume | 42 |
| No | 2 |
| Specialist publication | U.S. Pharmacist |
| State | Published - Feb 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacy
- Pharmacology
- Pharmaceutical Science
Cite this
Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation. / Hoie, Eric B.; O’Brien, Karen K.; Neighbors, Katie; Castillo, Shana L.; Begley, Kimberley J.
In: U.S. Pharmacist, Vol. 42, No. 2, 01.02.2017, p. 32-35.Research output: Contribution to specialist publication › Article
}
TY - GEN
T1 - Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation
AU - Hoie, Eric B.
AU - O’Brien, Karen K.
AU - Neighbors, Katie
AU - Castillo, Shana L.
AU - Begley, Kimberley J.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.
AB - Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.
UR - http://www.scopus.com/inward/record.url?scp=85013946037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013946037&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85013946037
VL - 42
SP - 32
EP - 35
JO - U.S. Pharmacist
JF - U.S. Pharmacist
SN - 0148-4818
ER -